FDA Issues Emergency Use Authorization for Remdesivir
Remdesivir can be administered intravenously to treat COVID-19 patients with severe disease
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of...
Symptomatic Health Care Staff in U.K. Screened for COVID-19
Shift in transmission dynamics noted as of March 24, concurrent with steps to implement social distancing
Remdesivir May Accelerate Recovery From Severe COVID-19
Early results from NIH study promising, but Lancet study did not show significant clinical benefit
Psoriasis Tied to Higher Alzheimer Disease Risk
Among psoriasis patients, those on systemic treatment had lower risk for Alzheimer disease
Choice of Spinal Anesthesia Key to Early Ambulation After THA
Patients who received mepivacaine rather than bupivacaine more likely to ambulate at 3.5 hours
PFS Prolonged With Continuous Dabrafenib, Trametinib in Melanoma
Median PFS longer with continuous versus intermittent treatment, but overall survival similar
USPSTF: Behavioral Interventions Likely Prevent Tobacco Use
Primary care-feasible behavioral interventions have moderate net benefit for school-aged children
Thromboembolic Complications in COVID-19 Discussed
All hospitalized COVID-19 patients should be started on prophylactic low-molecular-weight heparin
Low Vitamin D, Smoking Predict Worse Cognitive Function in MS
Higher vitamin D predicted better cognitive performance, while smoking predicted worse performance
